17 Panel Dip Card
The 17 panel dip card is a fast, reliable, and easy-to-use urine screening device designed to
detect ten commonly abused drugs in a single test format. This multi-drug detection dip card
is widely used in workplaces, rehabilitation programs, probation monitoring, healthcare screening,
law enforcement, and personal testing where accurate and efficient drug screening is required.
Showing all 2 results
Dip card 17 Panel Detecting GAB, FEN, ETG & KRA, Short Date Sale, Experation Date, 12/13/2026, As low as $0.99
AMP, BAR, BUP, BZO, COC, EtG, FEN, KRA, MDMA, MET, MTD, OPI/MOR, OXY, PCP, TCA, THC, GABAForensic UseAs low As$ 0.99 $1.01 - $1.25
Dip card 17 Panel CLIA Detecting EDDP,FEN & NFYL, Short date Sale – Experation Date 02/11/27 – As low as $1.29
AMP, BAR, BUP, BZO, COC, FEN, MDMA, MET, MTD, NFEN, OPI/MOR, OXY, PCP, PPX, TCA, THC, EDDP, FEN 1ng/mlCLIA WAIVEDAs low As$1.29 $1.29 - $1.69
Bulk Pricing that Cuts the Budget in Half
Priority Shipping For Bulk Orders.
Dedicated Wholesale Representative.
Quality That Is Reliable For the Nation.
Key Features of 17 Panel Dip Card
The 17 Panel Dip Card is an advanced drug screening tool designed to simultaneously detect 17 different drugs or drug metabolites in a single urine sample. This test is widely utilized for comprehensive substance abuse screening in various professional and clinical environments.
Two Serenity 17 Panel Multi-Level Dip Cards — one Forensic Use Only, one CLIA Waived and FDA Approved — both currently available as short-date sale pricing. The FUO card at $0.99 adds Gabapentin, Kratom, and EtG to the professional baseline. The CLIA card at $1.29 adds clinical-grade FEN at 1ng/mL, Nor-Fentanyl (NFYL), EDDP methadone metabolite, and PPX under CLIA Waived certification. Results in 5 minutes. Same-day shipping.
-
Drug Coverage: Detects a broad spectrum of substances including common drugs of abuse like amphetamines, cocaine, opioids, benzodiazepines, THC, barbiturates, methadone, and more.
-
Results: Provides clear, easy-to-read results within approximately 5 minutes, facilitating prompt decision-making.
-
User-Friendly: The dip-and-read format requires no specialized equipment, making it suitable for point-of-care testing or on-site drug screening.
-
High Accuracy: Built-in control lines ensure test validity, while test lines indicate the presence or absence of each substance.
-
Application: Commonly used in workplaces, medical clinics, rehabilitation facilities, and law enforcement agencies for pre-employment screening, random testing, probation monitoring, and clinical assessments.
This panel allows for multi-substance detection, aiding organizations and healthcare providers in maintaining safety, compliance, and effective treatment outcomes.
17 Panel Multi Dip Card Test specifications
| Code | Full Substance Name | Cutoff | What It Catches / Notes |
|---|---|---|---|
| AMP | Amphetamines | 1000 ng/mL (FUO) 500 ng/mL (CLIA) |
Adderall, Vyvanse — CLIA card uses lower 500 ng/mL clinical cutoff for increased sensitivity. Standard on both cards |
| BAR | Barbiturates | 300 ng/mL | Phenobarbital, butalbital, secobarbital — standard on both cards |
| BUP | Buprenorphine | 10 ng/mL | Suboxone, Subutex — MAT compliance detection — standard on both cards |
| BZO | Benzodiazepines | 300 ng/mL | Xanax, Valium, Klonopin, Ativan — standard on both cards |
| COC | Cocaine | 300 ng/mL (FUO) 150 ng/mL (CLIA) |
Cocaine, crack cocaine — CLIA card uses lower 150 ng/mL clinical cutoff. Standard on both cards |
| EDDP | Methadone Metabolite (EDDP) | 300 ng/mL (CLIA only) | Primary urinary metabolite of methadone — confirms methadone was ingested and metabolized, not added to specimen. CLIA card only |
| EtG | Ethyl Glucuronide | 300 ng/mL (FUO only) | Alcohol metabolite up to 80 hours post-consumption. FUO card only — CLIA card does not include EtG |
| FEN | Fentanyl | 20 ng/mL (FUO) 1 ng/mL (CLIA) |
Illicit fentanyl and analogs — FUO uses standard 20 ng/mL forensic threshold. CLIA uses clinical 1 ng/mL — 20x more sensitive. Standard on both cards |
| GABA | Gabapentin | 1000 ng/mL (FUO only) | Neurontin, pregabalin — widely misused in opioid populations, not detected on any standard panel. FUO card only |
| KRA | Kratom | 500 ng/mL (FUO only) | Mitragyna speciosa — opioid receptor activity, passes all OPI/BUP/MTD panels. FUO card only |
| MDMA | MDMA / Ecstasy | 500 ng/mL | Ecstasy, Molly — standard on both cards |
| MET | Methamphetamine | 1000 ng/mL (FUO) 500 ng/mL (CLIA) |
Crystal meth — CLIA card uses lower 500 ng/mL clinical cutoff. Standard on both cards |
| MTD | Methadone | 300 ng/mL | Methadone maintenance — standard on both cards. CLIA card also includes EDDP metabolite confirmation |
| NFYL | Nor-Fentanyl (Nor-Fentanyl metabolite) | 5 ng/mL (CLIA only) | Primary urinary metabolite of fentanyl — extends fentanyl detection window beyond parent compound. CLIA card only |
| OPI/MOR | Opiates / Morphine | 300 ng/mL | Heroin, codeine, morphine — standard on both cards |
| OXY | Oxycodone | 100 ng/mL | OxyContin, Percocet — standard on both cards |
| PCP | Phencyclidine | 25 ng/mL | PCP, angel dust — standard on both cards |
| PPX | Propoxyphene | 300 ng/mL (CLIA only) | Darvocet, Darvon — withdrawn from US market but still encountered in clinical and forensic toxicology screening. CLIA card only |
| TCA | Tricyclic Antidepressants | 1000 ng/mL | Amitriptyline, nortriptyline, doxepin — standard on both cards |
| THC | Marijuana / Cannabis | 50 ng/mL | Cannabis, edibles, concentrates — standard on both cards |
Red codes appear on only one of the two cards. CLIA card uses lower clinical cutoffs on AMP (500), MET (500), COC (150), and FEN (1 ng/mL). FUO card uses standard forensic cutoffs. Both cards include TCA — the only 17 panel dip card configuration in the range with TCA as a standard panel.
Choose Your 17 Panel Configuration
| Product | All 17 Panels | Type | From |
|---|---|---|---|
| 17 Panel FUO — GAB, KRA, EtG and FEN SHORT DATE SALE — Expiry 12/13/26 Best for treatment, corrections, sober living needing GAB and KRA with EtG alcohol monitoring |
AMP | BAR | BUP | BZO | COC EtG/300ng | FEN/20ng | GABA/1000ng | KRA/500ng MDMA | MET | MTD | OPI/MOR | OXY | PCP | TCA | THC |
Forensic Use Only | $0.90 |
| 17 Panel CLIA — EDDP, FEN/1ng and NFYL SHORT DATE SALE — Expiry 02/11/27 Best for methadone clinics, pain management, MAT programs needing CLIA Waived clinical fentanyl monitoring |
AMP/500 | BAR | BUP | BZO | COC/150 EDDP/300ng | FEN/1ng | NFYL/5ng | PPX/300ng MDMA | MET/500 | MTD | OPI/MOR | OXY | PCP | TCA | THC |
CLIA Waived FDA Approved |
$1.29 |
Both cards require a separate urine collection container. Results in 5 minutes. Forensic Use Only results require GC-MS or LC-MS/MS confirmation. CLIA Waived results may be documented clinically in settings holding a CMS Certificate of Waiver. For bulk pricing call 561-897-9238 or email [email protected].
Easy Steps To Use The 17 Panel Dip Card
Step 1 — Collect
Remove the drug test cup from its sealed pouch and use it as soon as possible. Have the subject provide a urine sample directly into the cup, filling to the indicated line.
Step 2 — Dip & Wait
At 2–4 minutes, verify the temperature of the specimen using the built-in temperature strip. A green indicator confirms the sample is valid and within the acceptable range of 90–100°F.
Step 3 — Read
Peel back the label when ready to interpret results. Read results within 5 minutes of collection. Do not read results after 8 minutes, as the extended window may affect accuracy.
Positive
Two colored bands appear — one in the control region (C) and one in the test region (T). This indicates no drug was detected above the cutoff level.
Negative
Two colored bands appear, one in the control region (C) and another in the test region (T) for the drug in question.
Invalid
The control band fails to appear entirely. Discard the test and retest with a fresh cup within 3 minutes. If the problem persists, contact your distributor.
What is Included in a 17 Panel Dip Card? The FUO with GAB and KRA, and the CLIA Waived Clinical Grade Card with FEN at 1ng/mL
The 17 panel dip card category from 12 Panel Now contains two fundamentally different Serenity Multi-Level Dip Cards sharing 14 common panels but serving entirely distinct clinical and forensic purposes. Both are currently available at short-date sale pricing. The Forensic Use Only card at $0.99 (expiry 12/13/26) adds Gabapentin, Kratom, and EtG to the professional baseline — covering three emerging substance detection gaps in a single forensic dip card. The CLIA Waived card at $1.29 (expiry 02/11/27) adds clinical-grade Fentanyl detection at 1 ng/mL, Nor-Fentanyl (NFYL) metabolite confirmation at 5 ng/mL, EDDP methadone metabolite confirmation at 300 ng/mL, and PPX — the most clinically sophisticated dip card configuration in the 12 Panel Now range.
What makes these two 17 panel cards fundamentally different in purpose and clinical function:
17 Panel FUO — GAB, KRA, EtG and FEN $0.99
Adds: GABA/1000ng + KRA/500ng + EtG/300ng + FEN/20ng — plus TCA as standard — to the 12-panel baseline
This card is designed for forensic programs dealing with polydrug-using populations where Gabapentin misuse, Kratom use as an opioid substitute, alcohol abstinence monitoring, and fentanyl detection are simultaneously required documentation priorities. GABA at 1000 ng/mL is the only available point-of-care detection for gabapentin — a substance widely misused in opioid treatment populations that passes every standard drug panel. KRA at 500 ng/mL detects Kratom, which acts on mu-opioid receptors but does not trigger any OPI, BUP, or MTD panel. EtG at 300 ng/mL provides 80-hour alcohol monitoring. FEN at 20 ng/mL covers fentanyl detection per the July 2025 SAMHSA federal mandate. TCA at 1000 ng/mL covers tricyclic antidepressants as a standard baseline panel. Forensic Use Only: all presumptive positives require GC-MS or LC-MS/MS confirmation. Short date expiry 12/13/26 — ideal for programs ordering to use within that period.
17 Panel CLIA Waived — EDDP, FEN/1ng and NFYL $1.29
CLIA Waived and FDA Approved. Clinical cutoffs on AMP/500, MET/500, COC/150. FEN at 1ng/mL. Adds: EDDP + NFYL/5ng + PPX — no EtG, no GAB, no KRA
This card is the most clinically sophisticated dip card configuration in the 12 Panel Now range. Four features distinguish it from every other dip card:
FEN at 1 ng/mL: The clinical-grade fentanyl threshold, 20 times more sensitive than the standard 20 ng/mL forensic cutoff. Designed to detect very low-level fentanyl concentrations from therapeutic transdermal patches, residual exposure in late-detection window specimens, or very recent low-dose exposure below the standard forensic threshold.
NFYL (Nor-Fentanyl) at 5 ng/mL: The primary urinary metabolite of fentanyl — produced by liver metabolism and detectable for longer than the parent compound after exposure. Extends the effective clinical fentanyl detection window and confirms that fentanyl was metabolized in the body rather than externally added to a specimen.
EDDP at 300 ng/mL: The primary urinary metabolite of methadone. Confirms that methadone was ingested and metabolized — a critical specimen validity consideration in methadone compliance monitoring where patients may add methadone to urine rather than ingest it.
CLIA Waived and FDA Approved: Per CMS CLIA regulations, settings holding a Certificate of Waiver can document results clinically without external laboratory confirmation. This card also uses lower clinical cutoffs: AMP at 500 ng/mL (vs 1000 ng/mL standard), MET at 500 ng/mL (vs 1000 ng/mL), COC at 150 ng/mL (vs 300 ng/mL) — improving sensitivity for residual therapeutic concentrations. Short date expiry 02/11/27 — longer window than the FUO card.
Panels Common to Both Cards: TCA Is on Both
Both 17 panel cards share common panels: AMP, BAR, BUP, BZO, COC, FEN, MDMA, MET, MTD, OPI/MOR, OXY, PCP, TCA, and THC. Notably, TCA (Tricyclic Antidepressants) at 1000 ng/mL is standard on both cards making the 17 panel range the most consistent TCA-inclusive configuration in the dip card range. The three FUO-only specialty panels are GABA, KRA, and EtG. The four CLIA-only specialty panels are EDDP, NFYL, PPX, and the clinical 1 ng/mL FEN cutoff (both cards detect FEN but at different thresholds).
Features and Benefits of 17 Panel Dip Test
Two 17 Panel Drug Test Dip Cards from 12 Panel Now — Two Entirely Different Clinical and Forensic Purposes at Short Date Sale Pricing: The 17 panel dip card range offers the widest regulatory and clinical divergence of any panel count in the range: a Forensic Use Only emerging-substance card at $0.99 covering Gabapentin, Kratom, EtG and Fentanyl, and a CLIA Waived clinical-grade card at $1.29 covering EDDP methadone metabolite confirmation, Nor-Fentanyl metabolite, and FEN at the clinical 1 ng/mL threshold.
- GABA at 1000ng/mL on the FUO Card: The Only 17 Panel Configuration That Detects Gabapentin: Gabapentin misuse in opioid-adjacent populations is documented extensively by NIDA prescription drug misuse research. No standard drug panel at any count detects it. The dedicated GABA panel at 1000 ng/mL on the FUO 17 panel card provides the only available point-of-care multi-panel gabapentin detection alongside a complete 17-substance professional baseline — including TCA, Kratom, EtG, and Fentanyl — for $0.99 per card on short date.
- FEN at 1ng/mL on the CLIA Card: 20x More Sensitive Than Standard Forensic Fentanyl Detection: The CLIA Waived 17 panel card detects Fentanyl at 1 ng/mL — the clinical threshold appropriate for transdermal patch compliance monitoring, very recent low-dose exposure, or residual therapeutic fentanyl concentrations that fall below the standard 20 ng/mL forensic threshold. This 1 ng/mL sensitivity level is not available on any other configuration in the 12 Panel Now dip card range at any price point.
- NFYL at 5ng/mL on the CLIA Card: Fentanyl Metabolite Detection That Extends the Detection Window: Nor-Fentanyl is the primary urinary metabolite of fentanyl, detectable for longer than the parent compound after exposure. The NFYL panel at 5 ng/mL on the CLIA card provides an extended fentanyl detection window and confirms that fentanyl was present in the body and metabolized — important for clinical documentation where the timing of exposure is a clinical question.
- EDDP at 300ng/mL on the CLIA Card: Methadone Metabolite Confirmation for MAT Compliance: EDDP confirms methadone was ingested and metabolized — not externally added to a specimen. A positive MTD panel alongside a negative EDDP panel suggests specimen manipulation. This built-in compliance validation capability is unique to the CLIA card in this range and is particularly valuable for methadone clinic programs where specimen integrity in compliance documentation is clinically significant.
- TCA at 1000ng/mL on Both Cards: The Only Panel Count Range Where TCA Is Standard on Every Configuration: Both 17 panel cards include TCA at 1000 ng/mL as a standard panel — covering tricyclic antidepressants (amitriptyline, nortriptyline, doxepin) in every 17 panel collection regardless of card selection. For programs where TCA monitoring is a protocol requirement, every 17 panel card delivers it without any configuration selection needed.
- Sale Pricing on Both Cards: $0.99 FUO and $1.29: Both 17 panel cards are currently available at short date sale pricing representing the lowest per-card price for these configurations. Programs ordering in bulk should confirm their projected usage volume fits within the expiry date before placing large orders. Contact 561-897-9238 to confirm current stock levels at short date pricing. Wholesale pricing and price beat available on all orders. Full OEM and private label available.
Contact for Bulk 17 Panel Dip Card Orders, Short Date Availability, Wholesale Pricing and Private Label: 561-897-9238 | [email protected]
Check other product variations
for Multi Dip Cards
From everyday staples to specialty products:
- Multi Strips
- 5 Panel Dip Cards
- 10 Panel Dip Cards
- 12 Panel Dip Cards
- 14 Panel Dip Cards
- 19 Panel Dip Cards
10 Panel Dip
13 Dip Panel
12 Panel Dip
Dip Cards
Wholesale and Private Label 17 Panel Dip Cards: Short Date Bulk Pricing from $0.99 FUO and $1.29 CLIA, OEM Available
12 Panel Now currently offers both configurations of the 17 Panel Dip Card at short-date sale bulk pricing. The Forensic Use Only card (GAB, KRA, EtG, FEN, TCA) starts at $0.99. The CLIA Waived card (EDDP, FEN/1ng, NFYL, PPX) starts at $1.29 per card. Both cards are available at tiered volume pricing — the larger the order, the lower the per-card cost. All orders placed before 3:00 PM EST ship the same day.
The $0.99 FUO card at this price point represents one of the highest-value specialty dip card offerings in the 12 Panel Now portfolio — a 17-substance Forensic Use Only card including Gabapentin, Kratom, EtG, TCA, and Fentanyl for under $1.00 per card. For programs with established inventory management that can order in volume this pricing offers significant per-card savings versus standard pricing. Similarly, the CLIA Waived card at $1.29 provides clinical-grade fentanyl monitoring (FEN/1ng, NFYL, EDDP) under CLIA Waived certification at short date pricing.
12 Panel Now guarantees a price beat on any current supplier's documented pricing for the same product configuration. Send your current quote to [email protected]. For current bulk volume pricing and to confirm available stock at short date pricing before placing a large order, call 561-897-9238 directly.
OEM and Private Label — 17 Panel Dip Card
12 Panel Now offers full OEM and private label programs for both 17 panel configurations. The Forensic Use Only GAB/KRA card and the CLIA Waived EDDP/NFYL card represent two distinct specialty products that are not widely available in private-label multi-panel dip card format from other manufacturers.
Private label options include:
- Custom foil pouch branding with organization logo, product name, and color scheme
- Custom card face printing with branded panel labeling and differentiated FUO vs CLIA Waived designation marking
- Custom outer box and case packaging for distributor resale programs
- Separate branded SKUs for the FUO and CLIA configurations within a single private label program
- OEM manufacturing to custom panel specifications for organizations requiring modifications to the standard 17 panel configuration
For distributors serving treatment networks, methadone clinic chains, pain management groups, and correctional systems, having both the FUO emerging-substance card and the CLIA clinical-grade card as separately branded products provides a complete point-of-care dip card portfolio covering the full spectrum from forensic screening to clinical documentation. Minimum order quantities and setup timelines available on request.
For wholesale accounts, private label setup, and OEM specifications contact:
12 Panel Now — Wholesale and Private Label
801 N Congress Ave, Boynton Beach FL 33426
561-897-9238 | [email protected]
12panelnow.com/wholesale | 12panelnow.com/private-label
What 12 Panel Now Offers:
220,000 Sq. Ft. Mega
Warehouse
We operate one of the largest drug-testing fulfillment centers in the country, stocked and ready to ship every day.
Lowest Wholesale Pricing. Highest Commissions. Period.
We aggressively price our products so you win more deals, while paying industry-leading commissions to our partners.
Same-Day Blind Drop Shipping
We ship directly to your customers — no branding, no invoices, no paper trail back to us. You keep the relationship. We do the heavy lifting.
Private Label Available
Want your own brand on the box? We’ve got you covered.
Build equity while selling proven products.
Real-Time Partner Portal
Track every order, commission, and customer in one clean dashboard. No guessing. No spreadsheets. Total transparency.
Where 17 Panel Dip Cards Are Used
| Setting | Best Card | Primary Applications | Why This Card |
| Methadone Clinics | 17 Panel CLIA Waived | Methadone compliance monitoring with EDDP metabolite confirmation, clinical-grade fentanyl concurrent use detection at 1 ng/mL and NFYL metabolite at 5 ng/mL, comprehensive opioid and stimulant baseline under CLIA Waived certification for clinical documentation | EDDP at 300 ng/mL confirms methadone was ingested and metabolized — a critical specimen validity check specific to methadone compliance monitoring. FEN at 1 ng/mL with NFYL at 5 ng/mL provides the most clinically sensitive fentanyl documentation available in dip card format. CLIA Waived status enables clinical record documentation without laboratory confirmation per CMS CLIA regulations. |
| MAT and Addiction Treatment Programs | 17 Panel FUO | Gabapentin misuse monitoring in opioid treatment populations, Kratom self-managed opioid substitute detection, EtG alcohol abstinence monitoring, fentanyl concurrent use detection alongside BUP and MTD compliance, TCA monitoring for co-prescribed antidepressants | GABA at 1000 ng/mL closes the single most significant point-of-care detection gap in MAT populations. KRA at 500 ng/mL closes the Kratom gap. EtG at 300 ng/mL covers the weekly alcohol monitoring interval per SAMHSA MAT guidelines. TCA covers co-prescribed antidepressants. All five specialty needs addressed in a single $0.99 card. |
| Pain Management Clinics | 17 Panel CLIA Waived | Fentanyl transdermal patch compliance monitoring at clinical 1 ng/mL sensitivity, TCA co-prescription compliance, comprehensive prescription opioid compliance at clinical cutoffs (AMP/500, MET/500, COC/150), CLIA Waived for clinical billing documentation | FEN at 1 ng/mL enables transdermal fentanyl patch adherence vs diversion documentation at clinical sensitivity. NFYL at 5 ng/mL confirms fentanyl was metabolized. Lower clinical cutoffs on AMP/MET/COC provide more sensitive detection of residual therapeutic concentrations. TCA at 1000 ng/mL covers co-prescribed antidepressants. CLIA Waived status supports clinical billing and record documentation. |
| Correctional Facilities | 17 Panel FUO | Gabapentin institutional contraband detection, Kratom supply monitoring, fentanyl supply contamination screening, alcohol monitoring via EtG, full stimulant and opioid baseline alongside TCA coverage | Gabapentin and Kratom are both documented institutional contraband substances that pass every standard cup screen. Fentanyl is confirmed in drug supply in all 50 US states per CDC overdose data. The $0.99 short date price makes this the most cost-effective institutional emerging-substance dip card available, covering Gabapentin, Kratom, Fentanyl, EtG, and TCA alongside the full professional baseline. |
17 Panel CLIA Waived Dip Card: Clinical-Grade Fentanyl at 1ng/mL, EDDP Methadone and Nor-Fentanyl The Most Sophisticated Clinical Dip Card Available
The CLIA Waived 17 panel dip card from 12 Panel Now is distinguished from every other configuration in the dip card range by three features that together constitute the most clinically complete fentanyl and opioid monitoring package available in a point-of-care dip format. First, FEN at 1 ng/mL — 20 times more sensitive than the standard 20 ng/mL forensic threshold — provides detection appropriate for transdermal fentanyl patch compliance, very recent low-dose exposure, and late-window specimens where parent compound concentration has dropped below forensic detection levels. Second, NFYL (Nor-Fentanyl) at 5 ng/mL detects the primary urinary metabolite of fentanyl, which is produced by liver N-dealkylation and remains detectable for longer than the parent compound — extending the effective clinical fentanyl detection window and providing metabolite confirmation evidence. Third, EDDP at 300 ng/mL confirms that methadone was actually ingested and metabolized rather than added externally to the specimen — the specimen validity tool that specifically addresses the documented behavior of adding methadone directly to urine to create a positive MTD result without actual consumption.
Combined with clinical cutoffs on AMP (500 ng/mL), MET (500 ng/mL), and COC (150 ng/mL), and CLIA Waived certification under CMS CLIA regulations, this card provides clinical documentation capability that no standard forensic dip card can match. For methadone clinics, buprenorphine programs, and pain management settings where clinical-grade fentanyl monitoring and methadone compliance documentation are required under CLIA Waived certification, the 17 panel CLIA card is the appropriate choice. Currently available at $1.29 per card in bulk on short date sale through February 2027. Contact 12 Panel Now at 561-897-9238 for current stock availability and bulk pricing.
17 Panel Forensic Use Only Dip Card with Gabapentin, Kratom, EtG and Fentanyl: Closing Four Simultaneous Detection Gaps for $0.99
The 17 Panel FUO Dip Card with GABA, KRA, EtG, FEN, and TCA from 12 Panel Now closes four specific detection gaps that no standard drug test at any panel count addresses: Gabapentin, Kratom, Alcohol (via EtG), and Fentanyl. Additionally, TCA (Tricyclic Antidepressants) is included as a standard panel — covering five substance categories not present on any standard 12 panel configuration in a single 17-substance Forensic Use Only card at $0.99 per card on short date sale through December 2026.
The population where all five of these specialty panels have documented relevance simultaneously is the opioid use disorder treatment and MAT clinic population. Per NIDA prescription drug misuse data, gabapentin misuse in opioid treatment populations is significantly documented — used to potentiate opioid effects, manage withdrawal, or as a mood-altering substance when opioids are unavailable. Kratom (Mitragyna speciosa) is legally sold in most US states and documented as a self-managed opioid substitute in MAT populations. EtG at 300 ng/mL provides 80-hour alcohol abstinence monitoring per SAMHSA MAT guidelines. Fentanyl at 20 ng/mL addresses illicit supply contamination per CDC overdose data. TCA covers co-prescribed antidepressants common in MAT populations. For programs that currently supplement a standard 12 panel card with separate GABA, KRA, EtG, FEN, and TCA add-on strips, the 17 panel FUO card consolidates all five into one $0.99 card per collection event.
What Does “Forensic Use Only” Mean for 17 Panel Dip Cards?
- What it means:CLIA Waived only tests determine program compliance - whether someone violated probation conditions, sober living rules, or custody requirements. They do not diagnose substance use disorder or guide medical treatment. Many courts require laboratory confirmation (GC-MS or LC-MS/MS) before admitting screening results as evidence.All results obtained from CLIA Waived & Fentanyl Drug Test Method tests should be treated as preliminary screening results only and must be confirmed by a certified laboratory using GC-MS (Gas Chromatography-Mass Spectrometry) or LC-MS/MS methodology before any legal, disciplinary, or medical action is taken.
- How results are used: Forensic use only tests determine program compliance - whether someone violated probation conditions, sober living rules, or custody requirements. They do not diagnose substance use disorder or guide medical treatment. Many courts require laboratory confirmation (GC-MS or LC-MS/MS) before admitting screening results as evidence.
- What it means: The product has not undergone FDA 510(k) clearance - the premarket notification process for medical devices. The FDA exercises enforcement discretion over these products because forensic settings have evidentiary protections (rules of evidence, chain of custody, confirmation requirements) not present in clinical settings.
17 Panel Dip Card Frequently Asked Questions
The 17 Panel Dip Card includes a broader range of substances, allowing organizations to screen for more drugs and metabolites in a single urine test compared to lower-panel options.
Results are typically available within minutes, making the test suitable for fast screening decisions in professional and clinical environments.
Yes. Many employers use multi-panel dip cards for pre-employment, random, post-accident, and reasonable-suspicion drug screening programs.
The Forensic Use Only version is intended for non-clinical screening programs, while the CLIA Waived version is designed for qualified healthcare settings that require clinical documentation.
No. The dip-card format is designed for simple on-site testing without the need for analyzers or laboratory instruments.
A 17-panel test provides expanded drug coverage, helping identify additional substances that may not be included in standard screening programs.
Yes. Treatment facilities often use comprehensive drug tests to monitor participant compliance and support recovery efforts.
Most users can perform the test by following the provided instructions, though organizations may implement internal training procedures.
The sample should be collected in a clean container and tested according to the manufacturer's instructions to maintain specimen integrity.
The result is considered invalid, and a new test should be performed using a fresh device and specimen.
The test detects specific drugs and metabolites within their respective detection windows, which vary depending on the substance and individual factors.
Yes. Comprehensive drug screening panels are commonly used in probation, corrections, and compliance monitoring programs.
It allows multiple substances to be screened simultaneously, reducing the need for separate tests and saving time.
Many organizations purchase in larger quantities to lower per-test costs and maintain adequate inventory levels.
Positive screening results should be considered preliminary and may require confirmation through certified laboratory testing methods.
Yes. Depending on the test configuration, some substances may be screened using different sensitivity thresholds.
Certain configurations are designed for healthcare environments and can support monitoring programs when used according to applicable regulations.
They should be kept in their sealed packaging and stored according to the manufacturer's recommended temperature and environmental conditions.
Common users include healthcare facilities, treatment centers, employers, correctional institutions, and safety-sensitive workplaces.
Yes. Many manufacturers offer private-label and OEM options for distributors, wholesalers, and organizations seeking custom branding.
